Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5TG5

OXA-24/40 in Complex with Boronic Acid BA8

Summary for 5TG5
Entry DOI10.2210/pdb5tg5/pdb
Related5TG4 5TG6 5TG7
DescriptorBeta-lactamase, {4-[(azetidin-1-yl)sulfonyl]phenyl}boronic acid, SULFATE ION, ... (6 entities in total)
Functional Keywordsinhibitor, complex, lactamase, oxa, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceAcinetobacter baumannii
Total number of polymer chains1
Total formula weight28481.13
Authors
Powers, R.A.,Werner, J.P.,Mitchell, J.M. (deposition date: 2016-09-27, release date: 2017-01-11, Last modification date: 2023-11-15)
Primary citationWerner, J.P.,Mitchell, J.M.,Taracila, M.A.,Bonomo, R.A.,Powers, R.A.
Exploring the potential of boronic acids as inhibitors of OXA-24/40 beta-lactamase.
Protein Sci., 26:515-526, 2017
Cited by
PubMed Abstract: β-lactam antibiotics are crucial to the management of bacterial infections in the medical community. Due to overuse and misuse, clinically significant bacteria are now resistant to many commercially available antibiotics. The most widespread resistance mechanism to β-lactams is the expression of β-lactamase enzymes. To overcome β-lactamase mediated resistance, inhibitors were designed to inactivate these enzymes. However, current inhibitors (clavulanic acid, tazobactam, and sulbactam) for β-lactamases also contain the characteristic β-lactam ring, making them susceptible to resistance mechanisms employed by bacteria. This presents a critical need for novel, non-β-lactam inhibitors that can circumvent these resistance mechanisms. The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are of particular concern, given that they efficiently hydrolyze potent carbapenem antibiotics. Unfortunately, these enzymes are not inhibited by clinically available β-lactamase inhibitors, nor are they effectively inhibited by the newest, non-β-lactam inhibitor, avibactam. Boronic acids are known transition state analog inhibitors of class A and C β-lactamases, and are not extensively characterized as inhibitors of class D β-lactamases. Importantly, boronic acids provide a novel way to potentially inhibit class D β-lactamases. Sixteen boronic acids were selected and tested for inhibition of the CHDL OXA-24/40. Several compounds were identified as effective inhibitors of OXA-24/40, with K values as low as 5 μM. The X-ray crystal structures of OXA-24/40 in complex with BA3, BA4, BA8, and BA16 were determined and revealed the importance of interactions with hydrophobic residues Tyr112 and Trp115. These boronic acids serve as progenitors in optimization efforts of a novel series of inhibitors for class D β-lactamases.
PubMed: 27997706
DOI: 10.1002/pro.3100
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.75 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon